TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Population:~All patients already scheduled for biopsy because of a raised Prostate-Specific Antigen (PSA) and/ or abnormal Digital Rectal Examination (DRE) in the Academic Medical Centre (AMC), excluding patients who do meet the exclusion criteria.~Inclusion criteria:~* age ≥ 18 years~* signed informed consent~Exclusion criteria:~* Has documented acute prostatitis or urinary tract infections.~* History of any clinically unstable cardiac condition including class III/IV cardiac failure or right-to-left shunts.~* Has had severe cardiac rhythm disorders within the last 7 days.~* Has severe pulmonary hypertension (pulmonary artery pressure \>90 mmHg) or uncontrolled systemic hypertension or respiratory distress syndrome~* Has received a biopsy procedure within 30 days before admission into this study~* Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study.~* Is incapable of understanding the language in which the information for the patient is given.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SonoVue (Type: OTHER): Ultrasound Contrast Agent

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Variation in Sulphonylurea Response in Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Age \>35 and \< 70~* Age of diabetes diagnosis \>35 and \<70~* White European~* Pre-SU HbA1c \<=10%~* HbA1c (on treatment) \<= 9%~* No myocardial infarction or Acute coronary syndrome in previous year~* No stroke or transient ischaemic attack in previous year~* No or stable (background) retinopathy (no unscheduled laser treatment in the last 6 months)~* eGFR \> 60mls/min~* No Proteinuria \>30mg/dl on multistix 10SG~* No active foot ulceration or infection~* Liver ALT ≤ twice the upper limit of the reference range~* Contactable by telephone~Exclusion Criteria:~* Type 1 diabetes~* HbA1c \>10% prior to commencing SU~* HbA1c\>9% on SU treatment~* Recent MI or Stroke within last 12 months~* Pre-proliferative or proliferative retinopathy~* eGFR\<60 ml/min~* Proteinuria \>30mg/dl on multistix 10SG~* Active foot ulceration or infection~* Liver ALT \> twice the upper limit of the reference range~* Female planning to conceive within the study period~* Any other significant medical reason for exclusion as determined by the investigator

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Withdrawal of sulphonylurea for 6 weeks, then re-introduction for 6 weeks, assessed by fasting glucose and HbA1c

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Morbid obesity~* Approved and scheduled for laparoscopic sleeve gastrectomy~Exclusion Criteria:~* Previous bariatric surgery~* Platelet count under 100,000~* Concurrent anticoagulation treatment~* Previous venous/atrerial thromboembolic event~* Known allergy to tranexamic acid~* History of heparin induced thrombocytopenia~* Oral contraceptive use~* Female hormonal replacement therapy~* Active thromboembolic state~* Genetic hypercoagulable state

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm (Type: ACTIVE_COMPARATOR): Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.
- Control Arm (Type: PLACEBO_COMPARATOR): Preoperative intravenous administration of 10ml normal saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rational Approach to a Unilateral Pleural Effusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with recurrent pleural effusion of unknown origin after a first pleural tap according to BTS guidelines.~2. Indication for thoracoscopy according to BTS guidelines.~3. Patients accept further investigation according to Danish and BTS guidelines.~4. Have received oral and written consent and agreed.~5. At the time of inclusion, above 18 years of age.~Exclusion Criteria:~1. Female patients: pregnancy or breastfeeding.~2. Lack of language comprehension.~3. Legally incompetent patients.~4. Life expectancy less than 3 month.~5. Contraindications to pleural tissue sampling.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pleuroscopy (Type: ACTIVE_COMPARATOR): According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.
- VATS (thoracoscopy) (Type: ACTIVE_COMPARATOR): According to BTS guideline thoracoscopy is the next procedure for patients who remain undiagnosed despite PET-CT and attempts to obtain biopsies. Eligible patients will be randomised to pleuroscopy or VATS. Patients with inconclusive pleuroscopy will proceed to VATS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Performance Study of an Artificial Nerve Guide (Reaxon® Nerve Guide) to Treat Digital Nerve Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. males and females between 18 and 65 years of age able to give his/her consent~2. a complete traumatic nerve injury of the common or proper digital nerve in the hand~3. a nerve defect of less or equal than 26 mm after release and approximation of the nerve ends and measured when the wrist is in neutral position~4. an injury that could conventionally be treated with implantation of a short nerve graft~5. nerve treatment initiated until 3 months after nerve injury~6. signed informed consent~Exclusion Criteria:~1. known allergy to chitosan and/or polyvinylpyrrolidone (PVP)~2. known impairment / previous diseases of the neural axis or previous lesions of the affected hand (of the digital nerve), which led to permanent sensory or motor restrictions of the hand/finger~3. complete amputation injury~4. known pregnant or breast-feeding females~5. disorders known leading to impaired wound healing (e.g. diabetes mellitus)~6. skin diseases in the wound area~7. impaired blood coagulation or bleeding disorders (e.g. because of regular intake of cumarin such as Marcumar)~8. pathologic blood flow disorders (e.g. Morbus Raynaud)~9. participated in another clinical investigation using an investigational new drug or device within 30 days prior to enrolment into this investigation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Reaxon® Nerve Guide (Type: EXPERIMENTAL): Implantation of Reaxon® Nerve Guide: If the subject is randomized to the Reaxon® Nerve Guide group, the surgeon will implant a Reaxon® Nerve Guide of ≤ 30 mm to bridge a nerve defect of ≤ 26 mm according to the method described in the instructions for use.
- Autologous Nerve Graft (Type: ACTIVE_COMPARATOR): Implantation of an autologous nerve graft: If the subject is randomized to the conventional treatment, the surgeon will repair the nerve by interposing an autologous nerve graft of ≤ 26 mm between the nerve ends.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Merits of Continuous Paravertebral Block in the Management of Renal/Adrenal Surgery by Laparotomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Patient scheduled for renal and/or adrenal surgery~* American Society of Anesthesiologists score ASA I, II, III~* Written informed consent given by the patient~Exclusion Criteria:~* Contraindication in the loco-regional anesthesia in the products of local anesthetic~* Surgery as a matter of urgency~* Pregnancy~* Congestive Cardiac insufficiency~* Severe hepatic Incapacity~* Disturbs of the coagulation~* Age \< 18 years~* ASA IV~* Patient already participating in a study or deadline 3-month-old subordinate since the end of a previous study~* Under guardianship Patient~* Psychiatric pathology or limitation of the intellectual abilities making difficult the understanding of the subjective questions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous Paravertebral block (Type: EXPERIMENTAL): Continuous Paravertebral block
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Antibiotic Treatment for Laparoscopic Inguinal Hernia Mesh Repair: Necessary or Not?

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Elective laparoscopic inguinal hernia repair, unilateral or bilateral~Exclusion Criteria:~* Those requiring antibiotics for the surgery;~* Those patients who have experienced surgical site infections from previous surgeries

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Antibiotic Prophylaxis (Type: None): This cohort will receive antibiotic prophylaxis prior to the hernia repair
- No Antibiotic Prophylaxis (Type: None): This cohort will not receive antibiotic prophylaxis prior to the surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Analgesic Effect of Beta 2-mimetics in the Treatment of Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults from 18 to 75 years old~* neuropathic painful condition following a thoracotomy or thoracoscopy for at least 3 months~Exclusion criteria:~* cardiovascular risk~* unstable diabetes mellitus~* allergy for terbutaline~* hypokaliemia without treatment~* untreated hypothyroidism~* HIV- or chemotherapy-induced neuropathy~* cancer being treated by chemo- or radio-therapy~* concomitant treatment with β-blockers, tricyclic ADs or morphine~* concomitant pain more severe than neuropathic pain- pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- first period with terbutaline and second period with placebo (Type: OTHER): The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.
- first period with placebo and second period with terbutaline. (Type: OTHER): The studies will be randomized, double-blind, placebo-controlled. It will use a 4 + 4 weeks crossover design for terbutaline vs. placebo (no titration). A washout period (2 weeks) will separate the treatment periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Any patient with a hematologic malignancy with residual disease (morphological, cytogenetic, molecular, or radiographic) after treatment with 1 or more chemotherapy regimens in whom achievement of remission with additional chemoradiotherapy is felt to be unlikely or who is in 3rd or greater CR. Patients with marrow based diseases in which the marrow biopsy does not meet criteria for active disease (i.e. \<5% blasts in acute leukemia) but who does not have full count recovery will be eligible for treatment on this high risk trial.~2. Patients must have two related donors that meet an acceptable scenario as described above.~3. Patients must adequate organ function:~   * LVEF of \>= 50%~  * DLCO (adjusted for hemoglobin) \>= 50% of predicted~  * Adequate liver function as defined by a serum bilirubin =\< 1.8, AST or ALT \< 2.5X upper limit of normal~  * Creatinine clearance of \>= 60 ml/min~4. Karnofsky Performance Status of \> 80 % on the modified KPS tool (see Appendix A).~5. Patients must be willing to use contraception if they have childbearing potential.~6. Able to give informed consent~Exclusion Criteria:~1. Modified KPS of \< 80%~2. \>= 5 Comorbidity Points on the HCT-CI Index (See Appendix B)~3. Class I or II antibodies against donor HLA antigens~4. HIV positive~5. Active involvement of the central nervous system with malignancy~6. Psychiatric disorder that would preclude patients from signing an informed consent~7. Pregnancy, or unwillingness to use contraception if they have child bearing potential~8. Patients with life expectancy of =\< 6 months for reasons other than their underlying hematologic/oncologic disorder~9. Alemtuzumab treatment within 8 weeks of HSCT admission.~10. ATG level of \>= 2 ugm/ml~11. Patients with active inflammatory processes (such as flair of an autoimmune disease) including T max \> 101, or active tissue inflammation are excluded.~12. Inability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment plan.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allogeneic HSCT Using Two Related Donors (Type: EXPERIMENTAL): CONDITIONING: Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.~TRANSPLANTATION: Patients undergo CD34+ selected allogeneic HSCT on day 0.~GVHD PROPHYLAXIS: Patients receive tacrolimus IV or PO beginning on day -1 with taper beginning on day 42 and mycophenolate mofetil IV or PO BID on days -1 to 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Bariatric Atrial Restoration of Sinus Rhythm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic persistent or paroxysmal AF refractory to at least one antiarrhythmic agent~* EF \> 40%~* BMI \> 40 or BMI \> 35 and at least one of the following co-morbidities:~  * Type 2 Diabetes Mellitus (by American Diabetes Association diagnostic criteria).~ * Systolic blood pressure of 130 mmHg and/or diastolic blood pressure 80 mmHg or higher despite medical treatment with maximal doses of three antihypertensive medications).~ * Refractory hyperlipidemia (acceptable levels of lipids unachievable with diet and maximum doses of lipid lowering medications).~ * Obesity-induced cardiomyopathy.~ * Clinically significant obstructive sleep apnea.~ * Obesity-related hypoventilation.~ * Pseudotumor cerebri (documented idiopathic intracerebral hypertension).~ * Severe arthropathy of spine and/or weight-bearing joints (when obesity prohibits appropriate surgical management of joint dysfunction treatable but for the obesity).~ * Hepatic steatosis without evidence of active inflammation.~ * Hypertriglyceridemia~ * Polycystic Ovary Syndrome (PCOS)~ * Asthma~ * Coronary Artery Disease (CAD)~Exclusion Criteria:~* Prior bariatric surgery~* Prior AF catheter ablation~* BMI \> 65 kg/m2~* Contraindication to bariatric surgery or AF ablation~* Contraindication to therapeutic anticoagulation~* Sustained AF lasting more than 3 years~* Left atrial diameter of greater than or equal to 60 mm or LA volume greater than or equal to 60 ml/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Atrial Fibrillation (AF) Catheter Ablation-Group A (Type: ACTIVE_COMPARATOR): Participants will undergo catheter ablation using either radiofrequency or cryo-ablation of pulmonary veins. Participants with persistent AF may also undergo roof and/or floor linear ablation with or without ablation of extra-pulmonary sites at the physician's discretion.
- Bariatric surgery prior to AF Catheter Ablation-Group B (Type: EXPERIMENTAL): Participants will undergo either a Roux-en-Y gastric bypass or a laparoscopic sleeve gastrectomy. The choice of the procedure will be based on numerous factors including current practice, the surgeon's and participant's choice, BMI, and the presence of certain comorbidities and their severity such as GERD, kidney stones, and past surgical history. Participants will undergo standard preoperative evaluation including dietary consultation and psychological evaluation during the eligibility process.~After bariatric surgery, in addition to routine post-surgical management, patients will follow up with cardiologist prior to AF catheter ablation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female with confirmed diagnosis of CF.~* Must have 1 of the following CFTR gating mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D.~* Hematology, serum chemistry, and coagulation at Screening with no clinically significant abnormalities or concomitant diagnosis that would interfere with the LCI and CT scan study assessments, as judged by the investigator.~Exclusion Criteria:~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1~* Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject (in the opinion of the investigator)~* Abnormal liver function, at Screening, defined as ≥3 × upper limit of normal (ULN), of any 3 or more of the following: serum aspartate transaminase (AST), serum alanine transaminase (ALT), gamma-glutamyl transpeptidase (GGT), serum alkaline phosphatase (ALP), and total bilirubin~* History of solid organ or hematological transplantation~* Any clinically significant non-CF-related illness within 2 weeks before Day 1~* Use of any moderate or strong inducers or inhibitors of cytochrome P450 (CYP) 3A within 2 weeks before Day 1~* Participation in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 terminal half-lives (whichever is longer or as determined by the local requirements) before Screening

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Part 1-Sequence 1 (Type: EXPERIMENTAL): ivacaftor in Treatment Period 1 →washout→placebo in Treatment Period 2
- Part 1 - Sequence 2 (Type: EXPERIMENTAL): placebo in Treatment Period 1→washout→ivacaftor in Treatment Period 2
- Part 2: ivacaftor (Type: EXPERIMENTAL): open label period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues